Clover Health Investments (CLOV) is "fully valued" after "a good job" improving core operations and medical costs, UBS Securities said Monday in a report initiating coverage of the company with a neutral rating.
Clover Health's Medicare Advantage star rating rose to 4.0 from 3.5, according to preliminary data indicated by the Centers for Medicare & Medicaid Services, boosting prospect for enrollment and revenue growth, UBS said.
In 2025, UBS projects revenue of $1.6 billion with $1.8 billion in 2026 with enrollment growth of 10% next year and 8% in 2026. "While positive on the company's trajectory and improvement, we see this as appropriately captured in the stock price today," the report said.
Clover Health's enrollment growth in its key state of New Jersey showed the company is only outperforming the market in a few core counties while lagging behind in most others, posing a near-term "headwind" to growth, UBS said.
UBS has a price target of $4 on Clover Health.
Shares of Clover Health slumped 8.8% in recent trading Monday.
Price: 3.6850, Change: -0.3550, Percent Change: -8.7871
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。